{
    "2020-04-06": [
        [
            {
                "time": "2020-03-15",
                "original_text": "Coronavirus update: New York possibly near apex, markets open the week higher",
                "features": {
                    "keywords": [
                        "Coronavirus",
                        "New York",
                        "apex",
                        "markets",
                        "higher"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-10",
                "original_text": "Top Stock Reports for J&J, Merck, Novartis & Others",
                "features": {
                    "keywords": [
                        "Stock Reports",
                        "J&J",
                        "Merck",
                        "Novartis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-04-12",
                "original_text": "The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "J&J",
                        "Sanofi",
                        "AstraZeneca",
                        "Lilly",
                        "Merck"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-14",
                "original_text": "Cramer Gives His Opinion Alteryx, Johnson & Johnson And More",
                "features": {
                    "keywords": [
                        "Cramer",
                        "Opinion",
                        "Alteryx",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}